二甲双胍对合并2型糖尿病的中晚期宫颈癌患者放化疗疗效的影响

Effect of metformin on efficacy of chemoradiotherapy in patients with advanced cervical cancer combined with T2DM

目的探讨二甲双胍对合并2型糖尿病（T2DM）的中晚期宫颈癌患者放化疗疗效的影响。方法 43例ⅡB~ⅢB期宫颈癌合并T2DM的患者随机分为两组,分别采用二甲双胍联合同步放化疗（试验组,23例）和口服其他降糖药联合相同同步放化疗（对照组,20例）。比较两组近期、远期疗效和不良反应。结果试验组客观缓解率高于对照组（73.9%vs.65.0%）,但差异无统计学意义（P〉0.05）。试验组和对照组中位疾病无进展生存期和中位总生存期比较差异无统计学意义（25.1个月vs.23.5个月和25.6个月vs.25.8个月）（P〉0.05）。试验组发生放射性膀胱炎比例高于对照组（P〈0.05）,而两组间发生胃肠道反应、骨髓抑制和放射性直肠炎的比例差异无统计学意义（P〉0.05）。结论二甲双胍可能对合并T2DM的中晚期宫颈癌患者放化疗具有增敏作用。

Objective To investigate the effect of metformin on the efficacy of chemoradiotherapy in the patients with advanced cervical cancer combined with type 2diabetes mellitus（T2DM）.Methods Forty-three patients with ⅡB-ⅢB cervical cancer combined with T2 DM were randomly assigned into two groups of A（treated with metformin and concurrent chemoradiotherapy,23cases）and B（treated with the same concurrent chemoradiotherapy combined with other oral antidiabetic medications,20cases）.The short-term and long-term clinical efficacy and adverse effects were compared between two groups.Results The objective response rate was slightly higher in group A than that in group B（73.9% vs.65.0%）（P〈0.05）.The median progress free survival and median overall survival period were not significantly different between groups of A and B（25.1 months vs.23.5months and 25.6months vs.25.8months）（P〈0.05）.The incidence of radiocystitis was higher in group A than that in group B（P〈0.05）.The proportion of gastrointestinal reaction,bone marrow suppression and factitial proctitis were not significantly different between two groups（P〈0.05）.Conclusion Metformin may be likely to enhance the sensitization of the patients with advanced cervical cancer combined with T2 DM to chemoradiotherapy.